Enoblituzumab Explained

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.

References

  1. http://www.ama-assn.org/resources/doc/usan/x-pub/enoblituzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Enoblituzumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.